Rapamycin inhibits Toll-like receptor 4-induced pro-oncogenic function in head and neck squamous cell carcinoma.
作者： GUOXIN REN , JINGZHOU HU , RUNXIANG WANG , WEI HAN , MEI ZHAO
DOI: 10.3892/OR.2014.3134
关键词: Cell 、 Cytokine 、 Cell growth 、 Head and neck squamous-cell carcinoma 、 Oncogene 、 Biology 、 Cell cycle 、 Cell biology 、 Apoptosis 、 TLR4
摘要: Toll-like receptor 4 (TLR4) is expressed in head and neck squamous cell carcinoma (HNSCC) cells associated with HNSCC cancer progression. Rapamycin has been proven to be efficient for the treatment of in vivo, yet mechanism not understood rapamycin demonstrates little effect in vitro. In present study, lines CAL27 SCC4 were pre-treated then stimulated a TLR4 ligand lipopolysaccharide (LPS). Cell proliferation, migration, invasion, resistance TRAIL-induced apoptosis, cytokine production, NF-κB p65 activation determined. The results indicated that LPS significantly invasion apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Pretreatment attenuated LPS-induced pro-oncogenic effects inhibiting LPS. siRNA knockdown demonstrated via TLR4. Hence, this study suggests may attenuating TLR4-induced effects.
utsystem.edu参考文章(31)
Laure Belmont, Nathalie Rabbe, Martine Antoine, Dominique Cathelin, Christophe Guignabert, Jonathan Kurie, Jacques Cadranel, Marie Wislez, Expression of TLR9 in tumor‐infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer International Journal of Cancer. ,vol. 134, pp. 765- 777 ,(2014) , 10.1002/IJC.28413
Yoh Dobashi, Shioto Suzuki, Hirochika Matsubara, Maiko Kimura, Shunsuke Endo, Akishi Ooi, Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas Cancer. ,vol. 115, pp. 107- 118 ,(2009) , 10.1002/CNCR.23996
Shile Huang, Mary-Ann Bjornsti, Peter J. Houghton, Rapamycins: mechanism of action and cellular resistance. Cancer Biology & Therapy. ,vol. 2, pp. 222- 232 ,(2003) , 10.4161/CBT.2.3.360
Li Mao, Waun K Hong, Vassiliki A Papadimitrakopoulou, Focus on head and neck cancer Cancer Cell. ,vol. 5, pp. 311- 316 ,(2004) , 10.1016/S1535-6108(04)00090-X
Qiaoling Sun, Qiuyang Liu, Yuanyuan Zheng, Xuetao Cao, Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation Molecular Immunology. ,vol. 45, pp. 2929- 2936 ,(2008) , 10.1016/J.MOLIMM.2008.01.025
Erika Vacchelli, Alexander Eggermont, Catherine Sautès-Fridman, Jerome Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, None, Trial Watch: Toll-like receptor agonists for cancer therapy. OncoImmunology. ,vol. 2, ,(2013) , 10.4161/ONCI.25238
J B Easton, P J Houghton, mTOR and cancer therapy. Oncogene. ,vol. 25, pp. 6436- 6446 ,(2006) , 10.1038/SJ.ONC.1209886
Clett Erridge, Endogenous ligands of TLR2 and TLR4: agonists or assistants? Journal of Leukocyte Biology. ,vol. 87, pp. 989- 999 ,(2010) , 10.1189/JLB.1209775
Sandrine Faivre, Guido Kroemer, Eric Raymond, Current development of mTOR inhibitors as anticancer agents Nature Reviews Drug Discovery. ,vol. 5, pp. 671- 688 ,(2006) , 10.1038/NRD2062
Shizuo Akira, Kiyoshi Takeda, Toll-like receptor signalling Nature Reviews Immunology. ,vol. 4, pp. 499- 511 ,(2004) , 10.1038/NRI1391